CD20 x CD3

Assets acting on this target.

Class
T-cell engaging bispecific antibody
Pathway
CD8/TCR-based T-cell engager bridging CD3+ T cells to CD20+ B cells for B-cell depletion

CD20 x CD3 bispecific antibodies are engineered to bind two different targets at once: CD20, a protein found on the surface of B lymphocytes (including malignant B cells in many lymphomas and leukemias), and CD3, part of the receptor complex present on nearly all T cells. By attaching to both cell types simultaneously, the antibody physically links a T cell to a B cell, creating a forced contact point called an immune synapse. This contact activates the T cell and triggers it to kill the attached B cell, regardless of what antigen that T cell would normally recognize. The biological rationale is to redirect a patient's existing T-cell population toward malignant or otherwise unwanted B cells without requiring prior immune priming against a tumor-specific antigen. This mechanism is broadly relevant in B-cell cancers, such as non-Hodgkin lymphomas and certain leukemias, where CD20 is consistently and stably expressed, and in some autoimmune diseases driven by pathogenic B cells. Compared with an antibody that targets CD20 alone, adding a CD3-binding arm converts B-cell elimination from a passive process, dependent on complement or natural killer cells, into an active, T-cell-driven killing mechanism that can operate even where those other effector systems are weak.

By indication

Related mechanisms

CD20 x CD3 drugs compared

5 drugs, stage by indication
5 drugs acting on CD20 x CD3: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
EpcoritamabAbbVie, Genmabbispecific antibodyApprovedApproved in Diffuse Large B-Cell Lymphoma; Approved in Follicular Lymphoma; Approved in High-Grade B-Cell Lymphoma; Approved in Large B-Cell Lymphoma
OdronextamabRegeneron Pharmaceuticalsbispecific antibodyPhase 3Phase 3 in B-Cell Non-Hodgkin Lymphoma; Phase 3 in Diffuse Large B-Cell Lymphoma; Phase 3 in Follicular Lymphoma; Phase 1 in Systemic Lupus Erythematosus
AZD5492AstraZenecabispecific antibody (trispecific T-cell engager)Phase 1/2Phase 1 in Rheumatoid Arthritis; Phase 1 in Systemic Lupus Erythematosus
CND261Candid Therapeutics, UCBbiologic (registry-typed, subtype undisclosed)Phase 1Phase 1 in Rheumatoid Arthritis
PlamotamabXencorbispecific antibodyPhase 1Phase 1 in Rheumatoid Arthritis

← all mechanisms